Press Resources

Large Xstrahl Logo

Xstrahl is the world’s leading designer and manufacturer of superficial orthovoltage medical X-ray systems, used in the treatment of cancers and dermatological disorders, and a leading pioneer and developer of advanced X-ray systems for pre-clinical radiation biology research. Headquartered in the UK with manufacturing facilities and offices in the UK, USA & Germany. Xstrahl also operates globally through its international network of distributors.

Large Xstrahl Medical Logo

For over 20 years, the comprehensive range of Xstrahl’s superficial and orthovoltage X-ray therapy systems (Xstrahl 100, 150, 200 and 300) have reliably supported the X-ray therapy requirements of healthcare professionals and their patients in over 700 clinics in 80 different countries around the world. Xstrahl have grown to be the leading designer and manufacturer of medical solutions that provide nonsurgical alternatives for patients with non-melanoma skin cancer, and treatment of benign and palliative conditions.

Large Xstrahl Life Sciences Logo

Xstrahl designs and delivers innovative X-ray research solutions to advance radiation oncology. Xstrahl’s pioneering X-ray research solutions include custom cabinet irradiators that are used for delivering precise radiation doses to in vivo and in vitro biological specimens, and the industry–leading Small Animal Radiation Research Platform (SARRP) image guided irradiator with high resolution imaging, and X-ray calibration systems used for calibrating laboratory X-ray research systems.

Press information contact: Neil Madle, Commercial Director

Adrian Treverton

Chief Executive Officer

Adrian had more than 10 years of industry leadership experience before coming to Xstrahl, as an International sales manager in 2006. As Sales Director, he took the lead on building up Xstrahl’s distributor network and growing the US subsidiary, ultimately moving to the USA in 2011 to continue his work with the Life Science brand. In 2013 Adrian was appointed Chief Operations Officer and continued to build a strong team around him. In 2017 after a management buy out Adrian was promoted to Group CEO.



System Logos

Click below to download our corporate brochure.

Recent Press Releases

November 1, 2018
Xstrahl Medical, global leaders in superficial radiotherapy devices and advanced radiation research systems, has appointed Neil Madle as Commercial Director – Radiotherapy. Based at Xstrahl’s UK head office in Surrey, Madle will be responsible for the commercial performance of the company’s radiotherapy business.


August 9, 2018
Sydney Vital, a translational cancer research centre funded by the Cancer Institute New South Wales (CINSW) and the University of Sydney, are the first centre in Austraila to acquire an Xstrahl Small Animal Radiation Research Platform (SARRP).


June 12, 2018
Xstrahl Medical and Electronica Y Medicina, S.A. (EYMSA) are able to announce a partnership that will enable Mexico to be supplied with next generation superficial radiotherapy systems for the treatment of non-melanoma skin cancers.

User Spotlights

Xstrahl Medical

The Xstrahl 150 is perfectly suited to treating a range of superficial and benign conditions thanks to its versatile design offering both orthovoltage and superficial treatment techniques in one system. Dr John Glees takes advantage of the system’s adaptability to treat a range of non-melanoma skin cancers and dermatological conditions such as Dupuytren’s and Ledderhose.


The Xstrahl 100 is perfectly suited for the treatment of superficial skin cancers, and with Australia recording skin cancer rates of 2 in 3 people, the need for an effective and versatile treatment method is needed. With a rise in cosmetically focused patients, Just Skin Treatment Clinic have partnered with the Xstrahl 100 to deliver highly beneficial results.


With skin cancer being the most common type of cancer in the USA the need for an effective and versatile treatment method is a necessity for many skin cancer centers. The Xstrahl 100 is perfectly suited for the treatment of superficial skin cancers, as used by the SCARS center in California.


Non-melanoma skin cancers (NMSC) are the most commonly diagnosed cancers in the world. Despite their relatively low malignant potential and mortality rate, NMSC are associated with a high morbidity and substantial treatment cost, and they significantly affect patient quality of life.


Xstrahl Life Science

The Radiobiology Research Group from the Centre for Cancer Research and Cell Biology at Queen’s University Belfast published a series of articles using SARRP to explore different translationally focused experimental approaches.


Immunotherapy has become the most promising advancement in cancer treatment. One of the institutions leading the advancement of this type of research is the Earle A. Chiles Research Institute at Providence Cancer Center.